ANDA 76073, held by Watson Labs. Nefazodone Hydrochloride.
As of Nov 16, 2026, ANDA 76073 (Nefazodone Hydrochloride), held by Watson Labs, was first approved by FDA on Sep 16, 2003, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2003 | Original application | Approved | None posted |
| Nefazodone Hydrochloride100MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride150MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride200MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride250MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Jun 24, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 15, 2005 | Supplement 3Labeling | Approved | None posted |
| Sep 16, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters